Evangelos Karavas

Evangelos Karavas


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
AVAntonios Vlachopoulos
Antonios Vlachopoulos
GKGeorgia Karlioti
Georgia Karlioti
EVANGELIA BALLAEVANGELIA BALLA
EVANGELIA BALLA
VDVasileios Daniilidis
Vasileios Daniilidis
TKTheocharis Kalamas
Theocharis Kalamas
Dimitrios BikiarisDimitrios Bikiaris
Dimitrios Bikiaris
The sustained release of pharmaceutical substances remains the most convenient way of drug delivery. Hence, a great variety of reports can be traced in the open literature associated with drug delivery systems (DDS). Specifically, the use of microparticle systems has received special attention during the past two decades. Polymeric microparticles (MPs) are acknowledged as very prevalent carriers toward an enhanced bio-distribution and bioavailability of both hydrophilic and lipophilic drug substances. Poly(lactic acid) (PLA), poly(lactic-co-glycolic acid) (PLGA), and their copolymers are among the most frequently used biodegradable polymers for encapsulated drugs. This review describes the current state-of-the-art research in the study of poly(lactic acid)/poly(lactic-co-glycolic acid) microparticles and PLA-copolymers with other aliphatic acids as drug delivery devices for increasing the efficiency of drug delivery, enhancing the release profile, and drug targeting of active pharmaceutical ingredients (API). Potential advances in generics and the constant discovery of therapeutic peptides will hopefully promote the success of microsphere technology.

Verified
Journal Article
Open access
PDF file
Panoraia I. SiafakaPanoraia I. Siafaka
Panoraia I. Siafaka
Neslihan Üstündağ OkurNeslihan Üstündağ Okur
Neslihan Üstündağ Okur
EKEvangelos Karavas
Evangelos Karavas
Dimitrios BikiarisDimitrios Bikiaris
Dimitrios Bikiaris
Nanocarriers, due to their unique features, are of increased interest among researchers working with pharmaceutical formulations. Polymeric nanoparticles and nanocapsules, involving non-toxic biodegradable polymers, liposomes, solid lipid nanoparticles, and inorganic–organic nanomaterials, are among the most used carriers for drugs for a broad spectrum of targeted diseases. In fact, oral, injectable, transdermal-dermal and ocular formulations mainly consist of the aforementioned nanomaterials demonstrating promising characteristics such as long circulation, specific targeting, high drug loading capacity, enhanced intracellular penetration, and so on. Over the last decade, huge advances in the development of novel, safer and less toxic nanocarriers with amended properties have been made. In addition, multifunctional nanocarriers combining chemical substances, vitamins and peptides via coupling chemistry, inorganic particles coated by biocompatible materials seem to play a key role considering that functionalization can enhance characteristics such as biocompatibility, targetability, environmental friendliness, and intracellular penetration while also have limited side effects. This review aims to summarize the “state of the art” of drug delivery carriers in nanosize, paying attention to their surface functionalization with ligands and other small or polymeric compounds so as to upgrade active and passive targeting, different release patterns as well as cell targeting and stimuli responsibility. Lastly, future aspects and potential uses of nanoparticulated drug systems are outlined.

Verified
Journal Article
Open access
PDF file
Panoraia I. SiafakaPanoraia I. Siafaka
Panoraia I. Siafaka
Neslihan Üstündağ OkurNeslihan Üstündağ Okur
Neslihan Üstündağ Okur
MMMariza Mone
Mariza Mone
SGSpyridoula Giannakopoulou
Spyridoula Giannakopoulou
SESevda Er
Sevda Er
Dimitrios BikiarisDimitrios Bikiaris
Dimitrios Bikiaris
In this work, a comparison between two different preparation methods for the improvement of dissolution rate of an antifungal agent is presented. Poly(ε-caprolactone) (PCL) electrospun fibers and β-cyclodextrin (β-CD) complexes, which were produced via an electrospinning process and an inclusion complexation method, respectively, were addressed for the treatment of fungal infections. Voriconazole (VRCZ) drug was selected as a model drug. PCL nanofibers were characterized on the basis of morphology while phase solubility studies for β-CDs complexes were performed. Various concentrations (5, 10, 15 and 20 wt %) of VRCZ were loaded to PCL fibers and β-CD inclusions to study the in vitro release profile as well as in vitro antifungal activity. The results clearly indicated that all formulations showed an improved VRCZ solubility and can inhibit fungi proliferation.

15 August 2019 in Sci
Verified
Journal Article
Open access
PDF file
Stavroula NanakiStavroula Nanaki
Stavroula Nanaki
RERodanthi Maria Eleftheriou
Rodanthi Maria Eleftheriou
Panagiotis BarmpalexisPanagiotis Barmpalexis
Panagiotis Barmpalexis
Margaritis KostoglouMargaritis Kostoglou
Margaritis Kostoglou
EKEvangelos Karavas
Evangelos Karavas
Dimitrios BikiarisDimitrios Bikiaris
Dimitrios Bikiaris
In the present study Aprepitant (APT) ternary solid dispersions (SDs) were developed and evaluated for the first time. Specifically, ternary SDs of APT with Poloxamer 188 and Soluplus® (SOL) were prepared via melt mixing and compared to binary APT/Poloxamer 188 and APT/SOL SDs. Initially, combined thermo-gravimetric and hot-stage polarized light microscopy studies indicated that all tested compounds were thermally stable up to 280 °C, while Poloxamer 188 acted as a plasticizer to SOL by significantly reducing the temperature required to fully solubilize the API during SD preparation. Differential scanning calorimetry combined with wide angle X-ray diffraction studies showed that crystalline API was dispersed in both binary and ternary SDs, while Fourier transformation-infrared spectroscopy studies revealed no molecular interactions among the components. Scanning electron microscopy combined with EDAX element analysis showed that the API was dispersed in nano-scale within the polymer matrices, while increasing APT content led to increasing API nano-crystals within the SDs. Finally, dissolution studies showed that the prepared formulations enhanced dissolution of Aprepitant and its mechanism analysis was further studied. A mathematical model was also investigated to evaluate the drug release mechanism.

10 September 2024 in Molecules
Verified
Journal Article
Open access
PDF file
CSCHRISTINA SAMIOTAKI
CHRISTINA SAMIOTAKI
IKIoanna Koumentakou
Ioanna Koumentakou
Ermis P. ChristodoulouErmis P. Christodoulou
Ermis P. Christodoulou
Nikolaos BikiarisNikolaos Bikiaris
Nikolaos Bikiaris
MVMarilena Vlachou
Marilena Vlachou
Panagiotis BarmpalexisPanagiotis Barmpalexis
Panagiotis Barmpalexis
Current transdermal drug delivery technologies, like patches and ointments, effectively deliver low molecular weight drugs through the skin. However, delivering larger, hydrophilic drugs and macromolecules remains a challenge. In the present study, we developed novel transdermal nanoneedle patches containing levofloxacin-loaded modified chitosan nanoparticles. Chitosan was chemically modified with transcutol in three ratios (1/1, 1/2, 1/3, w/w), and the optimum ratio was used for nanoparticle fabrication via the ionic gelation method. The successful modification was confirmed using ATR-FTIR spectroscopy, while DLS results revealed that only the 1/3 ratio afforded suitably sized particles of 220 nm. After drug encapsulation, the particle size increased to 435 nm, and the final formulations were examined via XRD and an in vitro dissolution test, which suggested that the nanoparticles reach 60% release in a monophasic pattern at 380 h. We then prepared transdermal patches with pyramidal geometry nanoneedles using different poly(lactic acid)/poly(ethylene adipate) (PLA/PEAd) polymer blends of varying ratios, which were characterized in terms of morphology and mechanical compressive strength. The 90/10 blend exhibited the best mechanical properties and was selected for further testing. Ex vivo permeation studies proved that the nanoneedle patches containing drug-loaded nanoparticles achieved the highest levofloxacin permeation (88.1%).